Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia

por Kim, Kibum, McMillin, Gwendolyn A., Bernard, Philip S., Tantravahi, Srinivas, Walker, Brandon S., Schmidt, Robert L.
Publicado 2019

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034

por Ali, Haris, Kishtagari, Ashwin, Maher, Keri, Mohan, Sanjay, Prchal, Josef, Wang, Xulong, Chamoun, Kamal, Tantravahi, Srinivas
Publicado 2023

A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

por Li, Peng, Venkatachalam, Shobi, Ospina Cordona, Daniela, Wilson, Lorena, Kovacsovics, Tibor, Moser, Karen A., Miles, Rodney R., Beck, David B., George, Tracy, Tantravahi, Srinivas K.
Publicado 2022

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

por Tantravahi, Srinivas K., Albertson, Daniel, Agarwal, Archana M., Ravulapati, Sowmya, Poole, Austin, Patel, Shiven B., Hawatmeh, Jamil S., Straubhar, Alli M., Liu, Ting, Stenehjem, David D., Agarwal, Neeraj
Publicado 2015

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

por Gill, David M, Stenehjem, David D, Parikh, Kinjal, Merriman, Joseph, Sendilnathan, Arun, Agarwal, Archana M, Hahn, Andrew W, Gupta, Sumati, Tantravahi, Srinivas Kiran, Samlowski, Wolfram E, Agarwal, Neeraj
Publicado 2016

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

por Patel, Ami B., Pomicter, Anthony D., Yan, Dongqing, Eiring, Anna M., Antelope, Orlando, Schumacher, Jonathan A., Kelley, Todd W., Tantravahi, Srinivas K., Kovacsovics, Tibor J., Shami, Paul J., O’Hare, Thomas, Deininger, Michael W.
Publicado 2020

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY

por Khorashad, Jamshid S., Tantravahi, Srinivas K., Yan, Dongqing, Mason, Clinton C., Qiao, Yi, Eiring, Anna M., Gligorich, Keith, Hein, Than, Pomicter, Anthony D., Reid, Alistair G., Kelley, Todd W., Marth, Gabor T., O'Hare, Thomas, Deininger, Michael W.
Publicado 2016

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

por Harrison, Claire N., Garcia, Jacqueline S., Somervaille, Tim C.P., Foran, James M., Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit, O'Connell, Casey L., Komrokji, Rami S., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen
Publicado 2022

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

por Eiring, Anna M., Page, Brent D. G., Kraft, Ira L., Mason, Clinton C., Vellore, Nadeem A., Resetca, Diana, Zabriskie, Matthew S., Zhang, Tian Y., Khorashad, Jamshid S., Engar, Alexander J., Reynolds, Kimberly R., Anderson, David J., Senina, Anna, Pomicter, Anthony D., Arpin, Carolynn C., Ahmad, Shazia, Heaton, William L., Tantravahi, Srinivas K., Todic, Aleksandra, Moriggl, Richard, Wilson, Derek J., Baron, Riccardo, O'Hare, Thomas, Gunning, Patrick T., Deininger, Michael W.
Publicado 2014